New and updated GLP-1 and metabolic medicine pages on ContentLora.https://contentlora.com/enhttps://contentlora.com/wiki/obicetrapib/https://contentlora.com/wiki/obicetrapib/Obicetrapib is an oral CETP inhibitor that lowers LDL cholesterol. EU-approved in September 2026 as Ubeslo and Evlarco; PREVAIL outcome data are pending.Sun, 11 Oct 2026 00:00:00 GMTWikihealthmetabolic-medicinelife-scienceshttps://contentlora.com/wiki/pcsk9-inhibitors/https://contentlora.com/wiki/pcsk9-inhibitors/PCSK9 inhibitors lower LDL cholesterol: evolocumab and alirocumab injections, twice-yearly inclisiran and the 2026 oral pill enlicitide (Lipfendra).Sun, 11 Oct 2026 00:00:00 GMTWikihealthmetabolic-medicinelife-scienceshttps://contentlora.com/wiki/statins/https://contentlora.com/wiki/statins/Statins are the first-line cholesterol drugs. How they work, the trial evidence on heart attacks and strokes, side effects and the muscle-pain question.Sun, 11 Oct 2026 00:00:00 GMTWikihealthmetabolic-medicinehttps://contentlora.com/events/cholesterol-and-fasting-tracker/https://contentlora.com/events/cholesterol-and-fasting-tracker/Live tracker of 2026 lipid and fasting news: the new US guideline, oral PCSK9 approval, obicetrapib in the EU, the pelacarsen miss and fasting trials.Sun, 11 Oct 2026 00:00:00 GMTDevelopinghealthmetabolic-medicinelife-scienceshttps://contentlora.com/analysis/intermittent-fasting-evidence-debate/https://contentlora.com/analysis/intermittent-fasting-evidence-debate/Weighing randomised trials against observational studies on intermittent fasting: weight, cholesterol, the 8-hour eating death signal and competing views.Sun, 11 Oct 2026 00:00:00 GMTAnalysishealthmetabolic-medicinelongevityhttps://contentlora.com/explain/cholesterol-explained/https://contentlora.com/explain/cholesterol-explained/What LDL, HDL, triglycerides and Lp(a) mean, what counts as high, how diet and drugs lower cholesterol, and what the 2026 US guideline changed.Sun, 11 Oct 2026 00:00:00 GMTExplainerhealthmetabolic-medicinehttps://contentlora.com/explain/cholesterol-lowering-drugs-guide/https://contentlora.com/explain/cholesterol-lowering-drugs-guide/A sourced guide to statins, ezetimibe, bempedoic acid, PCSK9 drugs, inclisiran, oral enlicitide (Lipfendra) and obicetrapib: how they work and the evidence.Sun, 11 Oct 2026 00:00:00 GMTExplainerhealthmetabolic-medicinelife-scienceshttps://contentlora.com/explain/home-cholesterol-test-buyers-guide/https://contentlora.com/explain/home-cholesterol-test-buyers-guide/Home cholesterol meters versus mail-in lab kits: FDA clearance, published accuracy studies, what each measures and dated prices. We did no hands-on testing.Sun, 11 Oct 2026 00:00:00 GMTExplainerhealthmetabolic-medicinehttps://contentlora.com/explain/intermittent-fasting-explained/https://contentlora.com/explain/intermittent-fasting-explained/What intermittent fasting and time-restricted eating are, what randomised trials show for weight and cholesterol, and how to read the scary headlines.Sun, 11 Oct 2026 00:00:00 GMTExplainerhealthmetabolic-medicinelongevityhttps://contentlora.com/explain/lipoprotein-a-explained/https://contentlora.com/explain/lipoprotein-a-explained/What Lp(a) is, why it is mostly genetic, why every adult is now advised to test once, and what the 2026 pelacarsen trial failure means for treatment.Sun, 11 Oct 2026 00:00:00 GMTExplainerhealthmetabolic-medicinelife-scienceshttps://contentlora.com/wiki/cagrisema/https://contentlora.com/wiki/cagrisema/CagriSema combines the amylin analogue cagrilintide with semaglutide. Novo Nordisk's REDEFINE results, the miss against tirzepatide and its FDA review.Sat, 10 Oct 2026 00:00:00 GMTWikimetabolic-medicinehealthlife-scienceshttps://contentlora.com/wiki/eli-lilly/https://contentlora.com/wiki/eli-lilly/Eli Lilly makes tirzepatide (Mounjaro, Zepbound) and the GLP-1 pill Foundayo, and is developing retatrutide. Its 2026 results, pipeline and pricing.Sat, 10 Oct 2026 00:00:00 GMTWikimetabolic-medicinehealthlife-scienceshttps://contentlora.com/wiki/novo-nordisk/https://contentlora.com/wiki/novo-nordisk/Novo Nordisk is the Danish maker of semaglutide (Ozempic, Wegovy, Wegovy pill). Its GLP-1 history, 2025–2026 results, pipeline and pricing pressures.Sat, 10 Oct 2026 00:00:00 GMTWikimetabolic-medicinehealthlife-scienceshttps://contentlora.com/wiki/orforglipron/https://contentlora.com/wiki/orforglipron/Orforglipron (Foundayo) is Eli Lilly's once-daily small-molecule GLP-1 pill, FDA-approved for weight management in April 2026. Trial data and pricing.Sat, 10 Oct 2026 00:00:00 GMTWikimetabolic-medicinehealthlife-scienceshttps://contentlora.com/wiki/retatrutide/https://contentlora.com/wiki/retatrutide/Retatrutide is Eli Lilly's investigational GIP, GLP-1 and glucagon triple agonist. Phase 2 and TRIUMPH phase 3 results and its 2027 filing plan.Sat, 10 Oct 2026 00:00:00 GMTWikimetabolic-medicinehealthlife-scienceshttps://contentlora.com/wiki/semaglutide/https://contentlora.com/wiki/semaglutide/Semaglutide (Ozempic, Wegovy, Rybelsus, Wegovy pill) is Novo Nordisk's GLP-1 drug. Its trials, approvals, oral forms, prices and patent status in 2026.Sat, 10 Oct 2026 00:00:00 GMTWikimetabolic-medicinehealthlife-scienceshttps://contentlora.com/wiki/tirzepatide/https://contentlora.com/wiki/tirzepatide/Tirzepatide (Mounjaro, Zepbound) is Eli Lilly's dual GIP/GLP-1 agonist. Its trials, approvals, head-to-head data, sales and pricing as of 2026.Sat, 10 Oct 2026 00:00:00 GMTWikimetabolic-medicinehealthlife-scienceshttps://contentlora.com/events/metabolic-medicine-tracker/https://contentlora.com/events/metabolic-medicine-tracker/Live tracker of GLP-1 and obesity-medicine milestones: approvals, pills, triple agonists, outcome trials, Medicare coverage and pricing, 2023–2026.Sat, 10 Oct 2026 00:00:00 GMTDevelopingmetabolic-medicinehealthlife-scienceshttps://contentlora.com/analysis/glp-1-access-and-pricing-debate/https://contentlora.com/analysis/glp-1-access-and-pricing-debate/GLP-1 prices, Medicare's Bridge, negotiated prices, compounding and generics: the evidence on access in 2026 and the competing views on what comes next.Sat, 10 Oct 2026 00:00:00 GMTAnalysismetabolic-medicinehealthpolicyhttps://contentlora.com/analysis/glp-1-long-term-use-debate/https://contentlora.com/analysis/glp-1-long-term-use-debate/What happens when people stop GLP-1 drugs, what is known about muscle, nutrition and rare side effects, and the competing views on long-term use.Sat, 10 Oct 2026 00:00:00 GMTAnalysismetabolic-medicinehealthhttps://contentlora.com/explain/glp-1-outcome-trials-explained/https://contentlora.com/explain/glp-1-outcome-trials-explained/What the big GLP-1 outcome trials (SELECT, FLOW, ESSENCE, SURMOUNT-OSA, SURPASS-CVOT, evoke) found, how to read them, and what regulators approved.Sat, 10 Oct 2026 00:00:00 GMTExplainermetabolic-medicinehealthhttps://contentlora.com/explain/how-glp-1-drugs-work/https://contentlora.com/explain/how-glp-1-drugs-work/How incretin hormones like GLP-1 and GIP control insulin and appetite, and how drug designers stretched them into weekly shots, pills and multi-agonists.Sat, 10 Oct 2026 00:00:00 GMTExplainermetabolic-medicinehealthlife-scienceshttps://contentlora.com/explain/metabolic-medicine/https://contentlora.com/explain/metabolic-medicine/A sourced crash course on GLP-1 drugs: incretin biology, semaglutide, tirzepatide, pills and triple agonists, outcome trials, prices and coverage.Sat, 10 Oct 2026 00:00:00 GMTExplainermetabolic-medicinehealthlife-scienceshttps://contentlora.com/explain/obesity-as-a-disease/https://contentlora.com/explain/obesity-as-a-disease/Why WHO and a Lancet Commission now frame obesity as a chronic disease, what "clinical" versus "preclinical" obesity means, and BMI's limits.Sat, 10 Oct 2026 00:00:00 GMTExplainermetabolic-medicinehealth